DEF: Pasithea Therapeutics Seeks Shareholder Approval for Reverse Stock Split and Expanded Equity Plan to Maintain Nasdaq Listing

Pasithea Therapeutics Corp. will hold its Annual Meeting of Stockholders to vote on key proposals including a reverse stock split to address Nasdaq's minimum bid price requirement and an increase in authorized shares for its equity incentive plan.

Summary

• The Annual Meeting of Stockholders will be held virtually on September 3, 2025, at 9:00 AM Eastern Time.
• Shareholders will vote on the re-election of Alfred Novak and Simon Dumesnil as Class II directors.
• Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is proposed.
• An amendment to the 2023 Stock Incentive Plan is proposed to increase the maximum aggregate number of shares authorized for issuance by 1,750,000 shares, bringing the total to 2,014,221 shares.
• A reverse stock split of common stock is proposed, with a ratio ranging from one-for-two (1:2) to one-for-twenty (1:20), to be determined by the Board of Directors.
• The primary purpose of the reverse stock split is to regain and maintain compliance with Nasdaq's $1.00 Minimum Bid Price Requirement, as the stock closed at $0.72 per share on July 22, 2025.
• As of July 22, 2025, there were 7,443,577 shares of Common Stock outstanding.
• If the reverse split is implemented, the number of outstanding shares would range from 744,357 to 3,721,788, depending on the chosen ratio.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the explicit Nasdaq delisting threat and the 'going concern' warning from auditors. While the proposed actions (reverse split, increased equity pool) are aimed at addressing these issues, they are reactive measures to significant challenges rather than indicators of strong underlying performance or growth.

Positives

• The proposed increase in the 2023 Stock Incentive Plan shares aims to attract, motivate, and retain high-quality talent, aligning employee interests with stockholders.
• The reverse stock split, if successful, could improve the marketability and liquidity of the common stock, potentially attracting a broader range of institutional investors.
• Separation of the Chairman of the Board and Chief Executive Officer roles ensures independent oversight of management.

Negatives

• The company received a Nasdaq notice for non-compliance with the $1.00 Minimum Bid Price Requirement, indicating a risk of delisting.
• Marcum LLP's audit reports for fiscal years ended December 31, 2023, and 2024 included an explanatory paragraph regarding 'substantial doubt about the Company's ability to continue as a going concern'.
• A material weakness related to the review of the annual income tax provision was identified for fiscal year 2023, though it was remediated by December 31, 2024.
• There is no assurance that the proposed reverse stock split will increase the stock price proportionally or maintain Nasdaq compliance, and the price could decline further.
• The reverse stock split may decrease the liquidity of the common stock due to a reduced number of outstanding shares.
• The effective increase in authorized but unissued shares resulting from the reverse split could have a dilutive effect on earnings per share, book value per share, and voting rights of existing stockholders.
• Due to a prior 1:20 reverse stock split on January 2, 2024, if the new split is 1:13 or greater and the bid price fails before January 2, 2026, or if any ratio is used and the bid price fails within one year of implementation, Nasdaq may delist without a compliance period.

Risks

• Risk of delisting from Nasdaq due to failure to meet the $1.00 Minimum Bid Price Requirement.
• Uncertainty regarding the effectiveness of the reverse stock split in sustaining a higher stock price or improving marketability.
• Potential for a greater percentage decline in stock price if the market price decreases after the reverse split.
• Decreased liquidity of common stock due to a reduced number of outstanding shares post-split.
• Dilution of existing stockholder interests from future issuances of authorized but unissued shares.
• Risk of owning 'odd lots' (less than 100 shares) for some stockholders after the reverse split, potentially increasing transaction costs.
• The company's ability to continue as a going concern is subject to substantial doubt, as noted by the independent auditors.

Future Outlook

The company aims to maintain its Nasdaq listing by increasing its stock price through a reverse stock split. It also seeks to ensure sufficient equity compensation to attract and retain talent, which is deemed critical for future success and growth. The Board reserves the right to abandon the reverse split if it determines it is no longer in the company's best interest.

Management Comments

• "The Board strongly believes that the Reverse Split is necessary to maintain our listing on Nasdaq."
• "The ability to provide equity-based compensation to employees, officers, non-employee directors and other individual service providers is essential based on our liquidity position."
• "Our future success depends on our continued ability to attract, recruit, motivate and retain high-quality talent."

Industry Context

The proposals reflect common challenges faced by small-cap biotechnology companies, particularly maintaining stock exchange listings and attracting talent in a competitive industry. Low stock prices are a frequent issue for such companies, often leading to reverse stock splits as a compliance mechanism. The emphasis on equity compensation is standard practice in the biotech sector to incentivize and retain key personnel, given the long development cycles and high-risk nature of drug discovery.

Comparison to Industry Standards

• The company's need for a reverse stock split to meet Nasdaq's minimum bid price requirement is a common occurrence for smaller biotechnology firms, many of which struggle with stock valuation volatility and liquidity challenges.
• The practice of using equity incentive plans with evergreen provisions and seeking increased share authorization is standard across the biotech industry to align employee and executive incentives with long-term shareholder value, comparable to practices at companies like BioAtla and Intensity Therapeutics, where some of the company's directors also serve or have served.
• The 'going concern' explanatory paragraph in audit reports is a significant red flag, often seen in early-stage or struggling biotech companies that have not yet achieved profitability or secured sufficient funding, contrasting with more established, revenue-generating pharmaceutical companies.

Management Changes

Corporate Governance

Related Party Transactions

• Contract with PsychoGenics, Inc. for preclinical studies, totaling approximately $0.3 million in payments, where Dr. Emer Leahy, a Board member, is the CEO and a less than 5% owner.
• Consulting agreement with Prof. Lawrence Steinman, a director, for advisory services at $25,000 per quarter.

Stakeholder Impact

• Shareholders: Face potential dilution from the increased equity incentive plan shares and the effective increase in authorized shares post-reverse split. The reverse split aims to protect their investment by maintaining Nasdaq listing, but carries risks of further price decline and reduced liquidity. Fractional shares will be cashed out.
• Employees/Officers/Directors: Benefit from the expanded equity incentive plan, which is intended to provide competitive compensation and retention incentives.
• Nasdaq: The company is actively addressing compliance with listing rules to avoid delisting, which is beneficial for the exchange's integrity.

Next Steps

• Hold the Annual Meeting of Stockholders on September 3, 2025, to vote on the proposed matters.
• If approved, the Board will determine the exact ratio for the reverse stock split and its implementation date prior to the one-year anniversary of the Annual Meeting.
• The company will file a Current Report on Form 8-K with the SEC to report the final voting results of the Annual Meeting.
• If the reverse split is implemented, the company will file the Reverse Split Certificate of Amendment with the Delaware Secretary of State.
• The company intends to file a registration statement on Form S-8 covering the additional 1,750,000 shares of Common Stock if the 2023 Incentive Plan Amendment Proposal is approved.

Key Dates

Recommendation

The filing primarily addresses corporate governance and a defensive capital structure adjustment (reverse stock split) to maintain Nasdaq listing, rather than presenting new operational or financial performance data. The 'going concern' warning from auditors is a significant negative, indicating underlying financial challenges. While the reverse split is a necessary step to avoid delisting, its long-term effectiveness in driving sustainable share price appreciation is uncertain. The increased share pool for incentives is positive for talent retention but also introduces potential for future dilution. Given the mix of defensive actions and ongoing financial concerns, a 'hold' recommendation is appropriate, advising investors to monitor the effectiveness of the reverse split and the company's progress in addressing its going concern issues.

Keywords

Reverse Stock Split, Nasdaq Listing, SEC Filing, Proxy Statement, Equity Incentive Plan, Corporate Governance, Shareholder Meeting, Biotechnology, Pharmaceuticals, Stock Options, Restricted Stock Units, Auditor Ratification, Going Concern